^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IKZF1 deletion + CDKN2A deletion

    i
    Other names: IKZF1, IKAROS Family Zinc Finger 1, Zinc Finger Protein Subfamily 1A 1 (Ikaros), Protein Phosphatase 1 Regulatory Subunit 92, Ikaros Family Zinc Finger Protein 1, Lymphoid Transcription Factor LyF-1, DNA-Binding Protein Ikaros, ZNFN1A1, IKAROS, LYF1, IK1, IKAROS Family Zinc Finger 1 (Ikaros), CLL-Associated Antigen KW-6, Hs.54452, PPP1R92, PRO0758, CVID13, LyF-1, CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf, Cyclin-dependent kinase inhibitor 2A
    Entrez ID:
    1029; 10320
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    10ms
    Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations. (PubMed, Blood Adv)
    Additionally, somatic lesions involving ZEB2, SETD2, SH2B3, and CRLF2, were associated with reduced ex vivo imatinib sensitivity. Our data suggest that the poor prognostic value of IKZF1(plus) deletions is linked to intrinsic mechanisms of TKI resistance other than ABL1 kinase domain mutations in newly diagnosed pediatric and adult BCR::ABL1-positive BCP-ALL.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • SH2B3 (SH2B Adaptor Protein 3) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2)
    |
    CDKN2A deletion • IKZF1 deletion + CDKN2A deletion • ABL1 deletion
    |
    imatinib
    1year
    Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia (ASH 2023)
    This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No IMI001-07. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • JAK2 (Janus kinase 2) • KMT2A (Lysine Methyltransferase 2A) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NUP214 (Nucleoporin 214) • BLNK (B Cell Linker)
    |
    KRAS mutation • CDKN2A deletion • KMT2A rearrangement • MLL rearrangement • CRLF2 rearrangement • JAK2 mutation • IKZF1 deletion + CDKN2A deletion • CRLF2 mutation • ABL1 deletion
    over3years
    Gene Deletions and Prognostic Values in B-Linage Acute Lymphoblastic Leukemia. (PubMed, Front Oncol)
    Minimal residual disease (MRD) was also analyzed together with gene deletions and demonstrated that gene deletions have a negative impact on survival only in MRD positive PhB-ALL patients. In conclusion, gene deletions are closely related with the prognosis of adult PhB-ALL patients.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    CDKN2A deletion • IKZF1 deletion • IKZF1 deletion + CDKN2A deletion